Biosimilar and Follow-on Insulin: The Ins, Outs, and Interchangeability.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

14 citing papers in PubMed, 1 synthesis or guideline pooled it, 26 citations in OpenAlex.

1. Comparative Efficacy and Safety of Ultra-Long-Acting, Long-Acting, Intermediate-Acting, and Biosimilar Insulins for Type 1 Diabetes Mellitus: a Systematic Review and Network Meta-Analysis.Journal of general internal medicine · 2021
   Pooled it
2. Impact of two consecutive rounds of National Volume-Based Procurement (NVBP) for insulin on utilisation and structure: a quasi-experimental study using interrupted time series analysis in Hubei, China.BMJ open · 2026
   Article
3. Insulin Glargine Utilization and Spending Before and After the First Biosimilar Insulin Glargine: A Real-World Data Study.Journal of general internal medicine · 2025
   Article
4. Exploring cutting-edge approaches in diabetes care: from nanotechnology to personalized therapeutics.Naunyn-Schmiedeberg's archives of pharmacology · 2025
   Review
5. Comparative effectiveness and safety of insulin reference biologics versus biosimilars for types 1 and 2 diabetes mellitus: Protocol for a systematic review of real-world studies.PloS one · 2025
   Article
6. Insulin Analogs and the Mode of Insulin Delivery: Recent Advances and Challenges.Current pharmaceutical biotechnology · 2025
   Review
7. National Volume-Based Procurement (NVBP) exclusively for insulin: towards affordable access in China and beyond.BMJ global health · 2024
   Article
8. The First Interchangeable Biosimilar Insulin: Insulin Glargine-yfgn.Journal of diabetes science and technology · 2023
   Review
9. The Nuances Surrounding Insulin Prescribing.Clinical diabetes : a publication of the American Diabetes Association · 2023
   Article
10. Efficacy and Safety of LY2963016 Insulin Glargine in Chinese Patients with Type 1 Diabetes Previously Treated with Insulin Glargine (LantusDiabetes therapy : research, treatment and education of diabetes and related disorders · 2022
    Article
11. The impact of biosimilar insulins on the diabetes landscape.Journal of managed care & specialty pharmacy · 2022
    Article
12. MYL1501D Insulin Glargine: A Review in Diabetes Mellitus.BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy · 2020
    Review
13. Origins of the Crisis in Insulin Affordability and Practical Advice for Clinicians on Using Human Insulin.Current diabetes reports · 2020
    Review
14. Pharmacovigilance of biosimilars - Why is it different from generics and innovator biologics?Journal of postgraduate medicine
    Review

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

Authors and funding

2 authors at 1 institution in 1 country.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as